Literature DB >> 21372296

High-mobility group box-1 mediates toll-like receptor 4-dependent angiogenesis.

Qing Lin1, Xiao Ping Yang, Dan Fang, Xiangrong Ren, Hongyan Zhou, Jiazhu Fang, Xialin Liu, Shiyou Zhou, Feng Wen, Xiaohong Yao, Ji Ming Wang, Shao Bo Su.   

Abstract

OBJECTIVE: Inflammation is closely linked to angiogenesis, and Toll-like receptors (TLRs) are the key mediators of inflammatory responses. However, the impact of TLRs on angiogenesis is incompletely understood. In this study, we determined the involvement of TLRs in angiogenesis. METHODS AND
RESULTS: In a mouse model of alkali-induced corneal neovascularization (CNV), we found that CNV was attenuated in TLR4-/- but not TLR2-/- mice. Further study revealed that the absence of TLR4 led to decreased production of proangiogenic factors in association with reduced accumulation of macrophages at the site of wounds, which was associated with reduced expression of high-mobility group box-1 (HMGB1) protein, an endogenous ligand for TLR4. Topical application of HMGB1 to the injured cornea promoted CNV with increased macrophage accumulation in wild-type mice but not in TLR4-/- mice. HMGB1 treatment in vitro also promoted the production of proangiogenic factors by mouse macrophages in a TLR4-dependent manner. Furthermore, antagonists of HMGB1 and TLR4 reduced CNV and macrophage recruitment in the injured cornea of wild-type mice.
CONCLUSIONS: Our results suggest that the release of HMGB1 in the wounds initiates TLR4-dependent responses that contribute to neovascularization. Thus, targeting HMGB1-TLR4 signaling cascade may constitute a novel therapeutic approach to angiogenesis-related diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21372296      PMCID: PMC7394281          DOI: 10.1161/ATVBAHA.111.224048

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  63 in total

Review 1.  High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal.

Authors:  Michael T Lotze; Kevin J Tracey
Journal:  Nat Rev Immunol       Date:  2005-04       Impact factor: 53.106

2.  Endothelial cell toll-like receptor 4 regulates fibrosis-associated angiogenesis in the liver.

Authors:  Kumaravelu Jagavelu; Chittaranjan Routray; Uday Shergill; Steven P O'Hara; William Faubion; Vijay H Shah
Journal:  Hepatology       Date:  2010-08       Impact factor: 17.425

3.  Activation of toll-like receptor (TLR)2, TLR4, and TLR9 in the mammalian cornea induces MyD88-dependent corneal inflammation.

Authors:  Angela C Johnson; Fred P Heinzel; Eugenia Diaconu; Yan Sun; Amy G Hise; Douglas Golenbock; Jonathan H Lass; Eric Pearlman
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-02       Impact factor: 4.799

4.  Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization.

Authors:  Diego G Espinosa-Heidmann; Ivan J Suner; Eleut P Hernandez; Dagoberto Monroy; Karl G Csaky; Scott W Cousins
Journal:  Invest Ophthalmol Vis Sci       Date:  2003-08       Impact factor: 4.799

5.  VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment.

Authors:  Claus Cursiefen; Lu Chen; Leonardo P Borges; David Jackson; Jingtai Cao; Czeslaw Radziejewski; Patricia A D'Amore; M Reza Dana; Stanley J Wiegand; J Wayne Streilein
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

6.  Mechanisms of Toll-like receptor 4 (TLR4)-mediated inflammation after cold ischemia/reperfusion in the heart.

Authors:  David J Kaczorowski; Atsunori Nakao; Raghuveer Vallabhaneni; Kevin P Mollen; Ryujiro Sugimoto; Junichi Kohmoto; Brian S Zuckerbraun; Kenneth R McCurry; Timothy R Billiar
Journal:  Transplantation       Date:  2009-05-27       Impact factor: 4.939

Review 7.  Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1).

Authors:  Judy R van Beijnum; Wim A Buurman; Arjan W Griffioen
Journal:  Angiogenesis       Date:  2008-02-09       Impact factor: 9.596

8.  The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion.

Authors:  Allan Tsung; Rohit Sahai; Hiroyuki Tanaka; Atsunori Nakao; Mitchell P Fink; Michael T Lotze; Huan Yang; Jianhua Li; Kevin J Tracey; David A Geller; Timothy R Billiar
Journal:  J Exp Med       Date:  2005-03-28       Impact factor: 14.307

9.  Essential contribution of CCL3 to alkali-induced corneal neovascularization by regulating vascular endothelial growth factor production by macrophages.

Authors:  Peirong Lu; Longbiao Li; Yu Wu; Naofumi Mukaida; Xueguang Zhang
Journal:  Mol Vis       Date:  2008-09-05       Impact factor: 2.367

10.  Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE.

Authors:  Vilma Urbonaviciute; Barbara G Fürnrohr; Silke Meister; Luis Munoz; Petra Heyder; Francesco De Marchis; Marco E Bianchi; Carsten Kirschning; Hermann Wagner; Angelo A Manfredi; Joachim R Kalden; Georg Schett; Patrizia Rovere-Querini; Martin Herrmann; Reinhard E Voll
Journal:  J Exp Med       Date:  2008-12-08       Impact factor: 14.307

View more
  38 in total

1.  Toll-like receptor deficiency worsens inflammation and lymphedema after lymphatic injury.

Authors:  Jamie C Zampell; Sonia Elhadad; Tomer Avraham; Evan Weitman; Seth Aschen; Alan Yan; Babak J Mehrara
Journal:  Am J Physiol Cell Physiol       Date:  2011-11-02       Impact factor: 4.249

2.  The alarmin HMGB-1 influences healing outcomes in fetal skin wounds.

Authors:  Adrienne D Dardenne; Brian C Wulff; Traci A Wilgus
Journal:  Wound Repair Regen       Date:  2013-02-25       Impact factor: 3.617

Review 3.  TLRs, future potential therapeutic targets for RA.

Authors:  Hatem A Elshabrawy; Abdul E Essani; Zoltán Szekanecz; David A Fox; Shiva Shahrara
Journal:  Autoimmun Rev       Date:  2016-12-15       Impact factor: 9.754

4.  RELMα Licenses Macrophages for Damage-Associated Molecular Pattern Activation to Instigate Pulmonary Vascular Remodeling.

Authors:  Qing Lin; Chunling Fan; John T Skinner; Elizabeth N Hunter; Andrew A Macdonald; Peter B Illei; Kazuyo Yamaji-Kegan; Roger A Johns
Journal:  J Immunol       Date:  2019-10-14       Impact factor: 5.422

5.  High mobility group Box 1 inhibits human pulmonary artery endothelial cell migration via a Toll-like receptor 4- and interferon response factor 3-dependent mechanism(s).

Authors:  Eileen M Bauer; Richard Shapiro; Timothy R Billiar; Philip M Bauer
Journal:  J Biol Chem       Date:  2012-11-12       Impact factor: 5.157

6.  An adipoinductive role of inflammation in adipose tissue engineering: key factors in the early development of engineered soft tissues.

Authors:  Heidi E Lilja; Wayne A Morrison; Xiao-Lian Han; Jason Palmer; Caroline Taylor; Richard Tee; Andreas Möller; Erik W Thompson; Keren M Abberton
Journal:  Stem Cells Dev       Date:  2013-01-29       Impact factor: 3.272

7.  Abnormal expression of Toll-like receptor 4 is associated with susceptibility to ethanol-induced gastric mucosal injury in mice.

Authors:  Hui-hui Ye; Rong Hua; Le Yu; Ke-jian Wu; Su-juan Fei; Xia Qin; Ying Song; Jun-li Cao; Yong-mei Zhang
Journal:  Dig Dis Sci       Date:  2013-06-07       Impact factor: 3.199

Review 8.  Persistent adaptation by chronic alcohol is facilitated by neuroimmune activation linked to stress and CRF.

Authors:  George R Breese; Darin J Knapp
Journal:  Alcohol       Date:  2016-02-24       Impact factor: 2.405

9.  The cytokine mRNA increase induced by withdrawal from chronic ethanol in the sterile environment of brain is mediated by CRF and HMGB1 release.

Authors:  Buddy A Whitman; Darin J Knapp; David F Werner; Fulton T Crews; George R Breese
Journal:  Alcohol Clin Exp Res       Date:  2013-07-29       Impact factor: 3.455

Review 10.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.